Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

Roy W Beck1, Danielle L Chandler, Stephen R Cole

  • 1CHAMPS Analysis Center, Jaeb Center for Health Research, Tampa, FL 33613, USA. rbeck@jaeb.org

Annals of Neurology
|March 29, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptation of the Transition Readiness Assessment Questionnaire for Pediatric-Onset Multiple Sclerosis: Protocol for a User-Centered Design Approach.

JMIR research protocols·2026
Same author

Initial postoperative alignment versus long-term outcomes in intermittent exotropia surgery.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus·2026
Same author

Author Response: On the Limited Predictive Value of Prior Myopia Progression: Methodological Considerations for Clinical Prediction.

Investigative ophthalmology & visual science·2026
Same author

Does Past Myopia Progression Predict Future Progression?

Investigative ophthalmology & visual science·2026
Same author

3-in-one <sup>PD-1</sup>CAR Tregs: A bioengineered cellular therapy for target engagement, activation, and immunosuppression with reparative potential.

iScience·2025
Same author

Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies.

JAMA network open·2025

Interferon beta-1a (Avonex) treatment significantly reduced the risk of developing clinically definite multiple sclerosis (MS) and new MRI lesions in high-risk patients. The benefits were observed across various subgroups, including different presenting events and demographic factors.

Area of Science:

  • Neuroscience
  • Immunology
  • Radiology

Background:

  • Multiple Sclerosis (MS) is a chronic neurological disease characterized by demyelination.
  • Early intervention may alter disease progression.
  • The Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) investigated early treatment effects.

Purpose of the Study:

  • To evaluate the efficacy of interferon beta-1a (Avonex) in preventing clinically definite MS and MRI changes.
  • To assess treatment effects in subgroups based on clinical presentation, MRI findings, and demographics.

Main Methods:

  • 383 patients with a first demyelinating event and MRI evidence of subclinical demyelination were randomized.
  • Patients received corticosteroids followed by weekly intramuscular injections of interferon beta-1a (30 microg) or placebo.

Related Experiment Videos

  • Proportional hazards models analyzed the development of clinically definite MS and a combined MS/MRI outcome.

    • Main Results:

    • Interferon beta-1a showed a beneficial effect across all evaluated subgroups.
    • Adjusted rate ratios for developing clinically definite MS were significantly lower in optic neuritis (0.58), brainstem-cerebellar (0.40), and spinal cord (0.30) syndromes.
    • A significant benefit was also observed for the combined MS/MRI outcome in these subgroups.

    Conclusions:

    • Initiating interferon beta-1a treatment at the first clinical demyelinating event is beneficial for patients with subclinical demyelination.
    • The drug's positive impact extends to patients presenting with optic neuritis, brainstem-cerebellar syndromes, and spinal cord syndromes.
    • Treatment benefits were consistent across subgroups defined by baseline MRI parameters, gender, and age.